Takeda to build plasma bank in Indonesia, initial $30 million investment
New: The Health Ministry has granted Takeda permission for plasma fractionation, with a two-year review before the network is expanded nationwide.
The Indonesian government is working with Takeda to build a domestic plasma-derived medicine ecosystem, with an initial investment of up to $30 million, or around Rp539 billion, over two years. The first phase includes building several plasma banks in Indonesia. The Health Ministry has also designated Takeda as a pharmaceutical company authorized to carry out plasma fractionation, allowing it to handle plasma collection and staged processing for plasma-derived drug products. The partnership also involves BKPM and the Coordinating Ministry for Economic Affairs. The government said the move could strengthen national health resilience, expand access to plasma-based therapies and provide a basis for evaluation before the operating model is developed into a national plasma bank network.